ArticleChemical science2021
An amplification-free ultra-sensitive electrochemical CRISPR/Cas biosensor for drug-resistant bacteria detection.
Article in Chemical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 138 citations in OpenAlex.
- [Research Progress on the Application of CRISPR/Cas System in Rapid Testing of Drug-Resistant Bacteria in Clinical Practice].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Review
- Programmable CRISPR-Cas diagnostic platforms for rapid detection of uropathogens and antimicrobial resistance.Archives of microbiology · 2026Review
- Advances in the detection of Drug-Resistant bacteria: current trends and innovations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Advances in biosensors for bacterial detection and identification.World journal of microbiology & biotechnology · 2025Review
- DNA-directed electrochemiluminescence nanosphere with electrocatalysis-enhanced microfluidic arrays for rapid multibacterial detection.Science advances · 2025Article
- Electrochemical Biosensing for Antibiotic-Resistant Bacteria: Advances, Challenges, and Future Directions.Micromachines · 2025Review
- Review
- Analytical techniques and molecular platforms for detection and surveillance of antimicrobial resistance: advancements of the past decade.3 Biotech · 2025Review
- Reinvigorating AMR resilience: leveraging CRISPR-Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security-a systematic review.Tropical medicine and health · 2025Review
- New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14.Heliyon · 2025Review
- Synthetic biology meets Aspergillus: engineering strategies for next-generation organic acid production.World journal of microbiology & biotechnology · 2025Review
- Advances in the application of CRISPR technology in pathogen detection: amplification-based and amplification-free strategies.Frontiers in cellular and infection microbiology · 2025Review
- Advances in biosensor technologies for the detection of antimicrobial resistance inFrontiers in cellular and infection microbiology · 2025Review
- A Microfluidic Biosensor for Quantitative Detection ofBiosensors · 2024Article
- Recent Advances in CRISPR/Cas System-Based Biosensors for the Detection of Foodborne Pathogenic Microorganisms.Micromachines · 2024Review
- Recent Advances in the CRISPR/Cas-Based Nucleic Acid Biosensor for Food Analysis: A Review.Foods (Basel, Switzerland) · 2024Review
- Detection of biological loads in sewage using the automated robot-driven photoelectrochemical biosensing platform.Exploration (Beijing, China) · 2024Article
- CRISPR-Cas target recognition for sensing viral and cancer biomarkers.Nucleic acids research · 2024Review
- A novel electrochemical aptasensor based on NrGO-H-MnMikrochimica acta · 2024Article
- The application of CRISPR-Cas system inHeliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continued development of high-performance and cost-effective
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.